Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque

Simple item page
dc.contributor.authorEvans, Rhiannon
dc.contributor.authorLavín Plaza, Begoña
dc.contributor.authorPhinikaridou, Alkystis
dc.contributor.authorChooi, Kok Yean
dc.contributor.authorMohri, Zahra
dc.contributor.authorWong, Eunice
dc.contributor.authorBoyle, Joseph
dc.contributor.authorKrams, Rob
dc.contributor.authorBotnar, René
dc.contributor.authorLong, Nicholas
dc.date.accessioned2024-01-31T10:38:12Z
dc.date.available2024-01-31T10:38:12Z
dc.date.issued2020
dc.description.abstractCardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo.
dc.description.departmentDepto. de Bioquímica y Biología Molecular
dc.description.facultyFac. de Ciencias Químicas
dc.description.refereedTRUE
dc.description.sponsorshipBritish Heart Association
dc.description.sponsorshipKing’s College London
dc.description.sponsorshipImperial College London
dc.description.statuspub
dc.identifier.citationEvans RJ, Lavin B, Phinikaridou A, Chooi KY, Mohri Z, Wong E, Boyle JJ, Krams R, Botnar R, Long NJ. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque. Nanotheranostics 2020; 4(4):184-194. doi:10.7150/ntno.44712. https://www.ntno.org/v04p0184.htm
dc.identifier.doi10.7150/ntno.44712
dc.identifier.issn2206-7418
dc.identifier.officialurlhttps://doi.org/10.7150/ntno.44712
dc.identifier.urihttps://hdl.handle.net/20.500.14352/97000
dc.issue.number4
dc.journal.titleNanotheranostics
dc.language.isoeng
dc.publisherIvySpring
dc.rights.accessRightsopen access
dc.subject.cdu577.1
dc.subject.ucmBioquímica (Química)
dc.subject.unesco2302 Bioquímica
dc.titleTargeted molecular iron oxide contrast agents for imaging atherosclerotic plaque
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number4
dspace.entity.typePublication
relation.isAuthorOfPublication1f5cced3-0761-429d-a70e-4881fff2f7a9
relation.isAuthorOfPublication.latestForDiscovery1f5cced3-0761-429d-a70e-4881fff2f7a9
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Targeted_molecular_iron_oxide_contrast_agents.pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos